Related Experiment Video

Updated: Jun 2, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Targeting hepatitis B virus and human papillomavirus induced carcinogenesis: novel patented therapeutics

Rupinder K Kanwar1, Neha Singh, Sneha Gurudevan

  • 1Laboratory of Immunology and Molecular Biomedical Research, Centre for Biotechnology and Interdisciplinary Sciences, BioDeakin, Institute for Technology & Research Innovation, Deakin University, Geelong, Victoria, Australia. rupinder.kanwar@deakin.edu.au

Recent Patents on Anti-Infective Drug Discovery
|April 27, 2011
PubMed

Insights

Viral infections cause 10-15% of human cancers. This review highlights innovative strategies targeting hepatitis B virus (HBV) and human papillomavirus (HPV) to prevent virus-mediated carcinogenesis and associated cancers.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Viral infections are a significant risk factor, accounting for 10-15% of human cancers globally.
  • Hepatitis B virus (HBV) and human papillomavirus (HPV) are key oncogenic viruses with distinct global patterns.
  • Understanding viral pathogenesis and immune responses is crucial for developing targeted therapies.

Purpose of the Study:

  • To review innovative strategies for targeting HBV and HPV infections in cancer prevention.
  • To compare and contrast HBV and HPV in terms of global incidence, transmission, pathogenesis, and prevention.
  • To highlight recent advancements in vaccine and antiviral therapeutic development.

Main Methods:

  • Literature review focusing on HBV and HPV-mediated carcinogenesis.
  • Analysis of molecular pathogenetic and immune mechanisms.
  • Examination of viral surface antigens and oncoproteins for therapeutic targets.

Main Results:

  • Preventive vaccination programs for HBV and high-risk HPV have shown success in altering cancer incidence.
  • Insights into viral transmission and tumor progression have enabled targeted interventions.
  • Numerous patents and applications demonstrate progress in developing novel HBV and HPV targeting strategies.

Conclusions:

  • Targeted interventions against HBV and HPV are effective in reducing cancer burden.
  • Continued research into viral carcinogenesis mechanisms is vital for developing new therapeutic and prophylactic strategies.
  • Innovative strategies, including vaccines and antivirals, hold significant promise for future cancer prevention efforts.

More Related Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...